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Summary In this review an inventory is made of agents used to circumvent cis-diamminedichloroplatinum(II)
(CDDP) resistance in vitro and in vivo. Agents that affect CDDP accumulation and membrane related systems,
cytoplasmic defense mechanisms, as well as DNA accessibility and repair are reviewed.
In resistant cell lines that have decreased accumulation, this can be restored by hyperthermic treatment.
With or without effects on accumulation compounds that affect cell signal transduction often increase CDDP
cytotoxicity. Calcium channel blockers and calmodulin inhibitors do not seem to be uniformly good
modulators of CDDP resistance. For transduction modulators as well as cellular calcium affecting agents
mechanisms are mainly unclear or controversial. Glutathione appears, with the now available agents, to be the
most promising target for modulation of cytoplasmic defense mechanisms. At the nuclear level the inhibition
of DNA repair related enzymes as well as the use of modified nucleosides to interfere with repair is studied in
various cell lines. Results with these agents suggest opportunities for clinically feasible cytotoxicity modulation.
DNA accessibility could in vitro be affected, but seems to be an unreliable target for modulation. Whenever
possible the resistance mechanism affected and the mode of action of the modulator are discussed. As an
alternative for modulation another method of overcoming CDDP resistance namely the application of CDDP
analogues is considered.
CDDP, one of the most widely used antitumour drugs, has
demonstrated activity against several tumours, such as testi-
cular, ovarian, head and neck, and small cell lung cancer
(Loehrer & Einhorn, 1984). The existence of natural or the
development of so-called acquired resistance for this drug is a
major clinical problem. To investigate which mechanisms are
responsible for this resistance various CDDP resistant cell
lines as well as in vivo animal models have been established
(for review Andrews & Howell, 1990). These mechanisms
include, reduced drug accumulation and increased detoxifi-
cation of CDDP in the cellular cytoplasm. In the cell nucleus
decreased DNA accessibility and increased DNA repair may
play a role (reviews: Andrews & Howell, 1990; de Graeff et
al., 1988; Hospers et al., 1988b; Kelley & Rozencweig, 1989).
This increased repair is accompanied by increased amounts
of repair enzymes (Kraker & Moore, 1988b; Scanlon et al.,
1989a; Scanlon et al., 1989b) or the presence of DNA bind-
ing proteins recognising damaged DNA (Chu & Chang,
1990). Also changes in the thymidine triphosphate (TTP)
synthesis might be an indication for increased DNA repair,
as this process requires a source of deoxynucleotides (Scan-
lon et al., 1989a). The net effect of all these systems is
reduced DNA platination (Pt-DNA), and thus decreased
cytotoxicity, as the Pt-DNA interactions are considered to be
the main cytotoxic lesions induced by CDDP (Roberts &
Friedlos, 1987). A G2 block due to this damage eould in
some cells lead to apoptosis (Barry et al., 1990; Eastman,
1990). Table I shows an example of resistance mechanisms
encountered in the human ovarian carcinoma cell line A2780
after in vitro induction of CDDP resistance.
After the detection of the various mechanisms of CDDP
resistance many attempts have been made to overcome this
resistance in vitro and in vivo. In this review an inventory is
made of the modulators used to increase CDDP cytotoxicity
and their possible site of action. Firstly, agents will be de-
scribed that act on the membrane with or without an effect
on accumulation. Secondly, agents influencing systems at the
cytoplasmic level such as thiol content modulators are de-
scribed. Finally agents with activity at nuclear, especially the
DNA level, such as DNA repair inhibitors and chromatin
conformation modulators will be discussed. Also cancer
chemotherapeutic agents that synergistically increase CDDP
cytotoxicity, and the perspective of overcoming CDDP resist-
ance with a selection of CDDP analogues will be reviewed.
CDDP accumulation restoring and membrane active agents
The mechanism by which CDDP enters the cell is still poorly
understood. In many CDDP resistant cell lines reduced
CDDP accumulation was observed (for reviews: Andrews &
Howell, 1990; de Graeff et al., 1988; Hospers et al., 1988b;
Kelley & Rozencweig, 1989).
Recently, for two CDDP resistant human ovarian car-
cinoma cell lines, with reduced cellular CDDP, accumulation
related changes in the potentials of plasma- (A2780-CP) or
mitochondrial- (2008/Cl3*) membranes were described (An-
drews & Albright, 1991). In 2008/DDP cells a decreased
number of Na+,K+-adenosine triphosphatase molecules/mg
protein was found an indication for a role of Na+,K+-
adenosine triphosphatase in CDDP accumulation and resist-
ance (Andrews et al., 1991). On the other hand the increased
expression of a 200kD membrane glycoprotein in CDDP
resistant murine thymic lymphoma cells (Kawai et al., 1990)
coinciding with a decreased CDDP accumulation was re-
ported. However, no direct proof for the role of this protein
as a carrier is available.
Accumulation restoring andsignal transduction affecting agents
Modulation ofaccumulation has been achieved by treatments
that are thought to have membrane fluidising effects, such as
hyperthermia as well as with drugs that can be grouped as
membrane active and signal transduction modulators (Table
II). Accumulation could be affected by treatment of cells at
higher temperatures, in CDDP resistant as well as sensitive
cells. This increase led to improved cytotoxicity in the cell
lines described (Wallner et al., 1986; Toffoli et al., 1989;
Mansouri et al., 1989; Eichholtz-Wirth & Hietel, 1990).
Therefore hyperthermia may be a good modulator when it is
possible to reliably increase tumour temperature. As
temperature increase has also effects on processes at the
nuclear level further applicability of hyperthermia will be
discussed in that section. Various studies describe that CDDP
sensitivity can be influenced via interference with signal
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Table I Changes found in A2780 human ovarian caricnoma cells after in vitro
CDDP resistance induction
Changes found in
resistant cells A possible role for References
Reduced accumulation Membrane potential Andrews & Albright, 1991
Na+/K+ adenosine Andrews et al., 1991
triphosphatase
Increased detoxification Glutathione Batist et al., 1986
Metallothionein Schilder et al., 1990a
Increased DNA repair DNA synthesis Lai et al., 1988
Polymerase a Scanlon et al., 1989a
Polymerase P Scanlon et al., 1989a
Typa synthesis Scanlon et al., 1989a
Folate metabolism Scanlon et al., 1989a
aThymidine triphosphate.
Table II CDDP accumulation restoring agents
Mechanism Cyto-
Modulator affected toxicity References
Hyperthermia Accumulation 4 Wallner et al., 1986
4 Toffoli et al., 1989
4 Mansouri et al., 1989
4 Eichholtz-Wirth &
Hietel, 1990
Forskolin Accumulation, 4 Mann et al., 1991
signal transduction,
cAMP t
Dipyridamole Accumulation, 4 Howell et al., 1987
signal transduction, 4 Keane et al., 1990
cAMP 4
transduction pathways. Increased cellular cyclic adenosine
monophosphate (cAMP) after dipyridamole (Howell et al.,
1987) or forskolin (Mann et al., 1991) incubation led to
increased CDDP cytotoxicity in human ovarian carcinoma
sensitive and resistant to CDDP. After dipyridamole this
coincided with increased cellular CDDP accumulation and a
shift towards aquated CDDP in sensitive and resistant cells.
Forskolin increased CDDP accumulation only in the sen-
sitive cells. This correlated with a more pronounced effect on
cytotoxicity in sensitive compared with resistant cells. These
findings suggest a role for cAMP activated signal transduc-
tion, at least in ovarian carcinoma cell lines, in CDDP
efficacy and a possible route for modulation through this
system. Also in mice, dipyridamole plus CDDP decreased
tumour growth of human bladder and testicular carcinoma
xenografts more than CDDP alone (Keane et al., 1990).
Also with agents that effect signal transduction by the
protein kinase C (PKC) pathway effects on CDDP cytotoxi-
city have been achieved (Table III). Incubation with TPA for
24h optimally increased CDDP cytotoxicity in HeLa cells
(Basu et al., 1990), but had no effect in human head and
neck carcinoma cells (Basu et al., 1990). In both lines PKC
activation after short incubations, and down regulation after
long-term incubations was found. After tests with other TPA
analogues it was concluded that PKC activation correlated
with potentiation of CDDP in HeLa cells and that the head
and neck carcinoma cell line probably had a defect further
on in its transduction pathway. Short incubations with TPA,
coinciding with PKC activation, potentiated CDDP in resis-
tant and sensitive ovarian carcinoma cells (Isonishi et al.,
1990). But in a Walker rat carcinoma cell line 24 h TPA
incubation inhibited PKC activity and increased CDDP
cytotoxicity (Hofmann et al., 1988), as did other PKC
inhibitors such as staurosporine, tamoxifen, quercetin (Hof-
mann et al., 1988) and ilmofosine (Hofmann et al., 1989).
Other studies with signal transduction modulators were
performed without measurement of the second messengers.
Combination of tamoxifen with CDDP in a melanoma cell
line was synergistic, without changes in CDDP accumulation
or cellular glutathione (GSH) content (McClay et al., 1991).
In another melanoma line, 4-fold less sensitive to tamoxifen
no potentiation, by tamoxifen, of CDDP cytotoxicity was
found (McClay et al., 1991). Quercetin considered to be a
PKC inhibitor also potentiated CDDP activity in vivo,
although to a lesser extent, in human large cell lung cancer
xenografts in mice (Hofmann et al., 1990). Epidermal growth
factor (EGF) incubation increased sensitivity to CDDP in the
2008 and the colo 316 ovarian carcinoma cell lines, but not
in 2008/C13*. This effect was EGF concentration and EGF
receptor number dependent. In 2008/C13* a reduced number
of EGF receptors was detected, but this could not explain the
total lack of CDDP sensitisation by EGF. So 2008/C13* was
thought to be unresponsive due to a defect in the EGF
transduction pathway (Christen et al., 1990). Via signal
transduction alterations modulation of the expression of
oncogenes might be achieved. Cyclosporin A increased
CDDP sensitivity in the resistant ovarian carcinoma cell line
A278ODDP. This coincided in this line with reversal of c-fos
and H-ras expression (Kashani-Sabet et al., 1990), oncogenes
thought to be of importance in cellular CDDP sensitivity (for
review: Scanlon, 1989a). In CDDP resistant non-small cell
and small cell lung carcinoma cell lines incubation with
cyclosporin A led to an increased CDDP sensitivity in the
small cell lung carcinoma cell lines (Hong et al., 1988).
Based on the above mentioned studies modulation of
CDDP resistance with membrane active compounds is possi-
ble in vitro, although in some lines PKC activation and in
others PKC inhibition seemed to potentiate CDDP cytotoxi-
city. This contradiction might be due to the measurement of
PKC activity in cell lysates (Basu et al., 1990; Isonishi et al.,
1990) or in intact cells (Hofmann et al., 1988), as opposite
effects on PKC activity were found, for breast carcinoma
cells, when PKC was measured in either cell lysates or in
intact cells (Issandou et al., 1990). Another explanation
might be that in HeLa cells PKC activation (Basu et al.,
1990) and in Walker rat cells PKC inhibition (Hofmann et
al., 1988) coincides with growth arrest. So different actions of
PKC in both cell lines may lead to comparable results. OnMODULATION OF CIS-DIAMMINEDICHLOROPLATINUM(II) RESISTANCE
Table III Membrane active agents with no effect on CDDP
accumulation
Mechanism Cyto-
Modulator affected toxicity References
TPAa Signal transduction,. 4 Basu et al., 1990
PKCb 4
TPAa 24 h Signal transduction, 4 Hofmann et al., 1988
PKCb +
TPAa PKCb 4 4 Isonishi et al., 1990
Ilmofosine Signal transduction, 4 Hofmann et al., 1989
PKCb +
Quercetin Signal transduction, 4 Hofmann et al., 1988
PKCb i Hofmann et al., 1990
Staurosporine Signal transduction, 4 Hofmann et al., 1988
PKCb +
Tamoxifen Signal transduction, 4 Hofmann et al., 1988
OKCb i, t/- McClay et al., 1991
EGFC Signal transduction t/- Christen et al., 1990
Cyclosporin A Oncogene expression 4 Kashani-Sabet et al.,
1990b
a12-o-tetradecanoylphorbol-13-acetate. bProtein kinase C. cEpideral
growth factor.
the other hand the used inhibitors of PKC are not specific.
However the divergence of their other effects makes a
uniform result unlikely.
Many of the membrane active drugs can be applied in the
clinic and some were combined with CDDP already. For
instance in a group of patients with malignant melanoma, an
intrinsically resistant tumour, receiving combination
chemotherapy of alkylating agents plus CDDP, significantly
more responses were observed when tamoxifen (20 mg day-')
was added to the scheme (10% without vs 52% with tamoxi-
fen) (McClay et al., 1989; McClay et al., 1991). In another
study in patients with melanoma and the same chemothera-
peutic treatment more complete responses were achieved with
160 mg tamoxifen per day than with 40 mg per day (Berd et
al., 1991). Pharmacokinetic analysis showed that tamoxifen
peak plasma concentrations capable of CDDP resistance
modulation in vitro could be reached (Berd et al., 1991).
Cyclosporin A was combined with carboplatin in a phase I
study. Cyclosporin A levels of 2 pg ml-' could be achieved,
approaching concentrations used for in vitro modulation
(5 jg ml-), while the clinical maximal tolerable dose was not
yet reached (Morgan et al., 1991). Intraperitoneal administra-
tion of dipyridamole, although not yet combined with
CDDP, resulted in dipyridamole concentrations that would
be high enough to accomplish local effects on CDDP cyto-
toxicity (Chan et al., 1988). For other drugs studies determin-
ing their optimal doses when combined with CDDP will have
to be performed.
Calcium channel blockers, calmodulin inhibitors
In cancer therapy calcium channel blockers and calmodulin
inhibitors are known for their capacity to circumvent the
so-called multidrug resistance (MDR) by reducing the in-
creased drug efflux in these cells. They bind specifically to the
170 kD glycoprotein (P-glycoprotein) (Cornwell et al., 1987),
which is responsible for this outward drug transport (Kartner
et al., 1983); CDDP is not involved in MDR, as is shown by
the fact that several MDR cell lines remained sensitive to
CDDP (e.g. Toffoli et al., 1991) and that in CDDP resistant
cell lines no elevated P-glycoprotein expression nor a DNA
amplification of the MDR1 gene or an increased amount of
mRNA could be detected (Kuppen et al., 1988; Masuda et
al., 1988; Hospers et al., 1988a).
However over the last years efforts to increase CDDP
cytotoxicity by co-administration of several calcium channel
blockers and calmodulin inhibitors have been made (Table
IV). Ikeda et al. observed an increase in CDDP activity
against neuroblastoma transplants in mice, when they
administered verapamil simultaneously (Ikeda et al., 1987).
Table IV Calcium channel blockers, calmodulin inhibitors
Mechanismc Cyto-
Modulator affected toxicity References
Verapamila ? 4 Ikeda et al., 1987
Hong et al., 1988
Mansouri et al., 1989
Nifedipinea ? 4 Onoda et al., 1989
Onoda et al., 1990
Nimodipinea ? - Onoda et al., 1989
Nicardipinea ? - Onoda et al., 1989
Diltiazema Onoda et al., 1989
Calmidazoliumb ? - Onoda et al., 1989
Naphtalene- ? 4 Kikuchi et al., 1987
sulphonamidesb
Trifluoro- ? 4 Perez et al., 1990
perazineb - Onoda et al., 1989
aCalcium channel blocker. bCalmodulin inhibitor. cPossible mechanisms
not described.
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In in vitro studies no potentiating effect of verapamil was
found neither in CDDP sensitive and resistant mouse fibro-
sarcoma (Mansouri et al., 1989) nor in a panel of CDDP
resistant small cell and non-small cell lung carcinoma cell
lines (Hong et al., 1988). Nifedipine enhanced CDDP
cytotoxicity when added simultaneously with CDDP to mice
bearing resistant transplants of B16 melanoma. This was
demonstrated by reduction in primary tumour weight and
amount of lung metastases (Onoda et al., 1989), and also by
increased survival after excision of the primary tumour
(Onoda et al., 1990). In this same model no effect on CDDP
cytotoxicity was observed with other calcium channel
blockers (diltiazem, verapamil, nimodipine, nicardipine) or
two calmodulin inhibitors (trifluoperazine, calmidazolium)
(Onoda et al., 1989).
With respect to calmodulin inhibitors, it was possible to
prolong the survival of mice by treatment with naphtalene
disulphonamides after CDDP (Kikuchi et al., 1987). Trifluo-
perazine, in vitro, increased CDDP cytotoxicity 2-fold in both
sensitive human ovarian carcinoma cells and two sublines
with different degrees of resistance to CDDP (Perez et al.,
1990).
In the literature no information is available about the
effects, of the calcium channel blockers or the calmodulin
inhibitors on CDDP accumulation. Other mechanisms to be
considered are for example the influence of calcium channel
blockers on cellular ion transport.
Vassilev et al. (1987) observed that the opening time of
calcium channels of the endoplasmatic reticulum in a CDDP
resistant was longer than in a sensitive murine leukemia cell
line, which they suggested might lead to different activities of
calcium dependent cellular systems. This intracellular system
did not respond to nifedipine and only at high verapamil
concentrations reduction of the opening times, comparable
with the reductions in the sensitive line, were achieved. Or it
could be hypothesised that the earlier described changes in
membrane potential related to reduced accumulation in
CDDP resistant cells (Andrews & Albright, 1991) may be
reversed by calcium channel blockers. As in MDR cells with
altered plasma membrane potentials, verapamil reversed
these to sensitive levels again (Vayuvegula et al., 1988).
Agents with modulating effects via cytoplasmic (defense)
systems (Table V)
CDDP resistance in cell lines is often accompanied by an
increase in cellular thiol content, in the form of GSH or as
metallothioneins (MT) (for review see ref Meijer et al.,
1990a). Both compounds are suggested to have their activity,
in the cytosol, by covalently binding CDDP, thus decreasing
the amount of Pt that reaches the nucleus. By lowering this
thiol content it should be possible to get more CDDP to its
target, DNA.
Table V Agents
The synthesis of GSH can specifically be blocked by buthi-
onine sulfoximine (BSO). The results obtained in vitro with
BSO vary from complete restoration of CDDP sensitivity of
resistant lines (Hamilton et al., 1985; Hromas et al., 1987) to
partial reversal (Meijer et al., 1990b; Andrews et al., 1986;
Chen & Zeller, 1990b) or no effect at all (Richon et al.,
1987). It might be concluded from these results that the role
of GSH is controversial in CDDP resistance modulation. A
possible explanation is that some cells are capable of restor-
ing their GSH pool faster than others and that this highly
influences the outcome of these experiments. New data on
GSH modulation showed improved CDDP cytotoxicity when
GSH synthesis was inhibited up to 12 h after CDDP incuba-
tion (Robichaud & Fram, 1990). If the importance of thiol
depletion after CDDP treatment is confirmed modulation of
GSH could consist of BSO pretreatment followed by incuba-
tion with a strong GSH binding agent combined with CDDP.
Cinnamaldehyde and a-chlorocinnamaldehyde could serve
that purpose, they potentiated CDDP in vitro in a human
cervical carcinoma cell line (Dornish et al., 1989). This effect
was a result of the direct reaction of these two cinna-
maldehydes with cellular thiols, as supported by the demon-
stration that derivatives, that were unable to react with
thiols, did not affect CDDP cytotoxicity. In humans a phase
1 study with BSO, combined with L-Pam, has so far demon-
strated an effect on GSH levels of mononuclear leukocytes
(80% reduction) and of ascitic tumour cells (reduction
>80%) without unacceptable toxicity (LaCreta et al., 1991).
So effects of BSO induced GSH depletion, during and even
after CDDP administration, may be expected, if GSH is of
importance in cases of CDDP resistance.
In combination with GSH, the enzyme glutathione S-trans-
ferase (GST) might play a role in CDDP resistance, as it is
responsible for the conjugation of chemicals to the thiol
group. The activity of GST is also often found to be in-
creased in CDDP resistant cell lines (Teicher et al., 1987;
Saburi et al., 1989). The diuretic agent ethacrynic acid
showed in vitro potentiating activity, as inhibitor of GST, in
studies using alkylating agents (Tew et al., 1988; Nagourney
et al., 1990; Ringborg et al., 1990). No effect of ethacrynic
acid on CDDP cytotoxicity was found in the cell line GLC4,
and its CDDP resistant subline, GLC4-CDDP, neither after
continuous nor after short-time simultaneous incubations.
Also in a panel of small cell lung carcinoma cell lines no
effect of ethacrynic acid was found (Plumb et al., 1990).
Administered to patients, in combination with thiotepa,
ethacrynic acid reduced GST in mononuclear leukocytes to
50% of control levels in 42% of the patients (Schilder et al.,
1990b).
With respect to GSH and GST studies are in progress
establishing the expression of these parameters in patient
tumour biopsies. Results so far showed, varying correlations
of GSH and GST with tumour response in the diverse
tumour types and after various chemotherapy treatments (for
with modulating effects via cytoplasmatic (defense)
systems
Mechanism Cyto-
Modulator affected toxicity References
Buthionine Glutathione, + 4 Hamilton et al., 1985
sulfoximine DNA repair + + Hromas et al., 1987
t Meijer et al., 1990b
t Andrews et al., 1986
- Chen & Zeller, 1990
Richon et al., 1987
Robichaud & Fram,
1990
Cinnamaldehyde Glutathione Dornish et al., 1989
a-Chlorocinnam- Glutathione + Dornish et al., 1989
aldehyde
Ethacrynic acid Glutathione - Plumb et al., 1990
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review: Meijer et al., 1990a).
For MT it was widely demonstrated that cells with higher
MT content were less sensitive to CDDP (for review see:
Andrews & Howell, 1990). Various reports described cells in
which with other heavy metals, such as cadmium, elevated
MTs have been induced resulting in CDDP resistance. Only
in two studies cell lines were described in which after resist-
ance induced in vitro, by CDDP exposure, elevated amounts
of MTs have been found (Kasahara et al., 1991; Kelley et al.,
1988). This is surprising as CDDP, and its hydrolysis pro-
ducts, were shown to be capable of induction of MT syn-
thesis in mouse tissues in vivo (Farnworth et al., 1989). In cell
lines obtained from ovarian tumours of patients before and
after CDDP treatment, MT expression was not found to be
correlated to CDDP sensitivity (Schilder et al., 1990a). So,
although MTs were capable of detoxification of CDDP in
cells, elevation seemed not to be a resistance mechanism
consistently found. MTs have been induced in other organs
to protect them from CDDP toxicity in mice (Satoh et al.,
1988). Transient elevation of MT, leading to CDDP resist-
ance, could be induced in some cells with dexamethasone
(Basu, 1991) a drug used in the clinic to diminish emesis
caused by CDDP (Kris et al., 1985). As yet no means are
described by which it might be possible to down regulate
tumour MTs in order to improve CDDP efficacy.
Agents affecting nuclear and DNA related systems
Increased DNA repair capacity is found in several CDDP
resistant cell lines. This can be demonstrated by an increase
in unscheduled DNA synthesis, by reactivation of an
implanted platinated gene or by the disappearance of specific
Pt-DNA adducts (for review see: Andrews & Howell, 1990).
In recent studies it could be ascribed to the elevation of
various enzymes involved in DNA excision repair, the system
by which the repair of CDDP induced DNA damage is
carried out.
Polymerase and TTP synthesis inhibitors (Table VI)
In CDDP resistant sublines of a human colon carcinoma cell
line and A2780, a human ovarian carcinoma cell line, in-
creased mRNAs for polymerase a and P, as well as increased
enzyme activities were observed (Scanlon et al., 1989a; Scan-
lon et al., 1989b). Activity of polymerase P was elevated in a
CDDP resistant murine leukaemia cell line (Kraker &
Moore, 1988b). But in 2008/DDP, a CDDP resistant subline
of the 2008 ovarian carcinoma cell line, no increase in mRNa
levels for polymerase a and P were detected (Katz et al.,
1990a).
Aphidicolin is a specific inhibitor of polymerase a. It
potentiated CDDP activity in A2780 CDDP resistant cells
(A2780CP) (Masuda et al., 1988) and in 2008 as well as
2008/DDP cells in vitro (Katz et al., 1990a). In A2780CP this
increased cytotoxicity could be ascribed to an effect of
aphidicolon on the increased DNA repair of this cell line
compared to A2780, as measured by 3H-thymidine incorpora-
tion in non-replicative cells (Masuda et al., 1988), and by the
removal of DNA bound Pt (Masuda et al., 1990). In CDDP
resistant HeLa cells, with an enhanced capacity to reactivate
a CDDP damaged plasmid carrying a chloramphenicol acetyl-
transferase gene, aphidicolin addition reduced this enhanced
plasmid activation to the level of parental cells (Chao et al.,
1990; Chao et al., 1991). Aphidicolin glycinate, a water solu-
ble form of aphidicolin, combined with CDDP increased
survival of mice bearing a human ovarian tumour (Harrison
et al., 1990).
Inhibition of DNA synthesis and repair can also be
achieved with 1-P-D arabinofuranosylcytosine (Ara-C), either
by incorporation of the drug into DNA or by the inhibition
of polymerase a. Enhancement of CDDP cytotoxicity by
Ara-C was predominantly demonstrated in colon carcinoma
cells in vitro, using short time incubations of Ara-C with
CDDP (Trujillo & Yang, 1989; Trujillo et al., 1989). Also in
murine ovarian teratomas, in vivo, after 3 days simultaneous
treatment with both agents an increase in survival was
observed (Berek et al., 1989). In human ovarian carcinoma
cell lines in vitro (Howell & Gill, 1985; Trujillo et al., 1989),
in breast carcinoma (Trujillo et al., 1989) and in pancreatic
carcinoma transplants in mice (Kyriazis et al., 1985) however
no positive effect of the combination over CDDP alone was
observed. In the pancreatic tumours synergism was observed
when caffeine was added to the combination, this was also
seen for the addition ofhydroxyurea to CDDP plus Ara-C in
HT29 colon carcinoma cells (Swinnen et al., 1989). The
effects could be ascribed to delayed DNA repair, leading to
more DNA-Pt cross links still persisting 24 h after incubation
(Swinnen et al., 1989; Fram et al., 1987). In vitro the com-
bination of CDDP plus Ara-C seemed to have a more pro-
nounced activity against colon carcinoma cell lines, than
Table VI Polymerase and thymidine triphosphate synthesis inhibitors
Mechanism Cyto-
Modulator affected toxicity References
Aphidicolin Polymerase a 4'x Masuda et al., 1988
+ Masuda et al., 1990
4' Katz et al., 1990a
4' Chao et al., 1990
4 Chao et al., 1991
4 Harrison et al., 1990
Ara-Ca DNA repair/ 4 Trujillo & Yang, 1989
polymerase a 4/- Trujillo et al., 1989
4 Berek et al., 1989
Howell & Gill, 1985
Kyriazis et al., 1985
Ara_Ca + DNA repair/ 4 Kyriazis et al., 1985
caffeine polymerase ot
Ara-Ca + DNA repair/ 4 Swinnen et al., 1989
hydroxyurea polymerase a
AZTb Thymidine kinase/ 4 Nyce et al., 1990
polymerases 4 Scanlon et al., 1989a
5-FUc TTPd synthesis 4 Scanlon et al., 1986
4' Johnston & Allegra,
1990
a 1-p-D-arabinofuranosylcytosine. bAzidothymidine. CS-Fluorouracil. dThy-
midinetriphosphate.232 H. TIMMER-BOSSCHA et al.
against other tumour types, although the magnitude of res-
ponse varied among different colon lines. This specificity
might be an indication of the importance of polymerase a in
colon tumours that are intrinsically insensitive to various
chemotherapeutic agents. Reports of a clinical trial of Ara-C
and CDDP in patients with colon cancer showed a promising
response rate, with acceptable toxicity (Pasccon et al., 1990).
The combination of Ara-C plus hydroxyurea followed by
CDDP was also tested as a phase I regimen. Nephrotoxicity
was dose limiting, but responses were seen in patients
pretreated with CDDP, at achievable doses (Albain et al.,
1990).
Also for other nucleoside analogues CDDP enhancing
capacities were described, probably caused by their influence
on DNA repair. Recently the potentiation of CDDP by
azidothymidine (AZT), a thymidine analogue was described
in a human colonic adenocarcinoma cell line (Nyce et al.,
1990; Scanlon et al., 1989b) and in A2780 and A2780DDP
(Scanlon et al., 1990). Effects were more pronounced in the
resistant lines due to increased activity of thymidine kinase
and polymerase P in these cell lines. Increased thymidine
kinase activity, means more AZT phosphorylated to AZTTP,
this increased amount of AZTTP leads to more efficient
inhibition of polymerase P.
The combination of CDDP followed by 5-FU in vitro
showed synergistic toxicity in a human ovarian carcinoma
cell line (Scanlon et al., 1986). This was explained by the
increased amount of cellular folates found after CDDP
incubation, that might enhance the inhibition of thymidilate
synthase by 5-FU (Scanlon et al., 1986). In a human colon
carcinoma cell line also synergism of the combination
CDDP/5-FU, but in reversed sequence, was observed (John-
ston & Allegra, 1990), with no difference in thymidilate
synthase activity nor in the binding capacity of the enzyme.
But DNA damage caused by CDDP/5-FU was increased
compared to CDDP alone (Johnston & Allegra, 1990).
BSO is also capable to inhibit DNA repair, because of its
effect on the cellular GSH pool. In a study by Lai et al., BSO
induced GSH reduction inhibited DNA repair, possibly by
destabilising the DNA repair enzymes or by reduction of the
deoxyribonucleotide triphosphate pools (Lai et al., 1989). In
both GLC4 and GLC4-CDDP BSO preincubation was
capable of annihilation of total Pt-DNA repair (Meijer et al.,
1990b).
Agents with an effect on poly(adenosine diphosphate
ribosyt)ation (Table VII)
Important for the DNA repair processes is the enzyme
poly(adenosine diphosphate ribose) polymerase. Chen et al.
demonstrated that the inhibition of poly(ADP-ribosyl)ation
with nicotinamide or 3-aminobenzamide increased CDDP
cytotoxicity in Ehrlich ascites carcinoma and sarcoma 180
cells implanted in mice (Chen & Pan, 1988). Also the reversal
of CDDP resistance in a rat ovarian carcinoma cell line in
vitro (Chen & Zeller, 1990b; Zeller et al., 1991), and of the
same tumour implanted in nude mice was found (Chen &
Zeller, 1990a). In GLC4 and GLC4-CDDP coincubation for
4 days with 2, 4 or 5 mM 3-aminobenzamide did not enhance
CDDP cytotoxicity, nor did preincubation with 0.5 Lg ml-'
6-nicotinamide followed by incubation with 2 mM-3-amino-
benzamide plus CDDP.
Metoclopramide, a N-substituted carboxamide derivative
of benzamide, is used in the clinic as antiemetic drug. It
stimulated ADP-ribosylation in normal mononuclear leuko-
cytes in vitro (Pero et al., 1989), and sensitised a human
squamous cell carcinoma of the head and neck xenografted
in mice for CDDP (Kjellen et al., 1989). Metoclopramide at a
clinical achievable dose of 2 mg kg-' plus CDDP reduced the
amount of metastases of a murine lung adenocarcinoma
xenografted in mice more than CDDP alone (Tyson et al.,
1990).
Topoisomerase II affecting agents (Table VII)
Elevated activity of topoisomerase II was found in a nitrogen
mustard resistant Burkitt's lymphoma cell line (Tan et al.,
1987). This enzyme is involved in DNA conformation and its
activity affects replication, translation and possibly repair.
Efforts were made to evaluate the importance of this enzyme
in CDDP resistance and to enhance alkylating agent and
CDDP cytotoxicity with topoisomerase II inhibitors, such as
novobiocin and nalidixic acid. In GLC4-CDDP (De Jong et
al., 1990) and a CDDP resistant subline of murine leukaemia
(Waud et al., 1991), topoisomerase II activity was increased
compared to their sensitive mother lines. Novobiocin in-
creased CDDP cytotoxicity in vitro in Chinese hamster ovary
(CHO) cells, in a epipodophyllotoxin (VP16) resistant CHO
subline (Eder et al., 1990) and in vivo in FSaIIC fibrosarcoma
Table VII Agents affecting other nuclear and DNA related systems
Modulator
3-Amino-
benzamide
Metoclo-
pramide
Novobiocin
DFMOa
Mechanism
affected
Poly)ADP-
ribosyl)ation
Poly)ADP-
ribosyl)ation
Topoisomerase II
DNA accessibility
Cyto-
toxicity
+.
49
Hyperthermia DNA accessibility
Docosahexaenoic
acid
DNA accessibility ti-
aa-Difluoromethylornithine.
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(Eder et al., 1989; Eder et al., 1987). This potentiation was
also observed in GLC4 and GLC4-CDDP after short, high
novobiocin incubations (De Jong et al., 1991) but novobiocin
had this effect only in GLC4 after continuous incubations
with low concentrations (De Jong et al., 1990). In a human
mesothelioma and a breast cancer cell line (Sriram et al.,
1990) as well as in GLC4 and GLC4-CDDP (De Jong et al.,
1991) novobiocin incubation led to an increase in DNA
interstrand cross-links. In a CDDP resistant human ovarian
carcinoma cell line there was no effect of novobiocin modula-
tion (Katz et al., 1990b). Incubation with 0.5gi-g ml-'
nalidixic acid, started 3 h before CDDP addition and con-
tinued during a 4days culture did not increase CDDP sensi-
tivity of GLC4 and GLC4-CDDP. In a phase I trial of
novobiocin and cyclophosphamide, serum levels could be
acheived that in vitro and in vivo in mice were sufficient to
achieve cyclophosphamide potentiation. Partial response and
stable disease were observed in patients who had progression
on prior cyclophosphamide combination therapy (Eder et al.,
1991). These results may encourage the start of a trial of
novobiocin and CDDP.
Another example of affecting CDDP toxicity via topo-
isomerase II modulation could be the improved in vivo
activity that was observed when CDDP was combined with
VP16 (Schlabel et al., 1979; Sculier & Klastersky, 1984; Bosl
et al., 1985) an anticancer drug that forms so called cleavable
complexes with topoisomerase II. Cellular, mechanistic,
synergism of CDDP and VP16 could not be identified by
Tsai et al. after extensive in vitro experiments and statistical
calculations (Tsai et al., 1989). They suggested that the ap-
parent synergistic improvement of the in vivo therapeutic
index of CDDP combined with VP16 was due to nonoverlap-
ping toxicities. But an alternating regimen of first CDDP
followed by VP16 showed increased activity in V79 multicell
spheroids: cells were recruited into active proliferation by
CDDP, after which VP16 treatment was much more effective
(Durand & Vanderbyl, 1990). This recruitment could play a
role in tumours with a high growth fraction.
The determination ofhigher levels of DNA repair enzymes
started only recently. Of earlier developed CDDP resistant
cell lines no information about repair enzyme levels is
available. The importance of these increased activities is
therefore not yet clear. However when the role of the DNA
repair enzymes can be confirmed by future investigations,
their detection and quantitation with the use of specific
antibodies and probes against their mRNAs might be a way
to determine tumour cell resistance in tumour biopsies. In
addition this repair would offer a promising target for
modulation.
DNA accessibility modulators (Table VII)
In addition to direct inhibition of enzymes involved with
repair, effects on DNA accessibility and on repair systems
can be achieved via interference with the DNA conforma-
tional state. Changes in conformation are often suggested as
a possible mechanism of resistance, until now little is known
about the relevance of this phenomenon.
Polyamines are involved in conformation of DNA. Their
equilibrium can be modulated with a-difluoromethylornithine,
a specific inhibitor of ornithine decarboxylase. Coincubation
with difluoromethylornithine resulted in augmentation (Allen
& Natal, 1986; Chang et al., 1987) as well as reduction
(Oredsson et al., 1982; Hunter et al., 1990) of CDDP
cytotoxicity. But results are variably and highly schedule
dependent.
Hyperthermia appears to have, apart from effect on CDDP
accumulation, an effect on Pt-DNA cross-link formation
(Meyn et al., 1980; Herman et al., 1988). Meyn et al. reported increased cross-link formation in CHO cells, after
treatment with CDDP at 43°C. This might have been due to
increased accumulation, although this was not measured. In
vitro, temperatures of42°C and higher increased the rate of
the reaction of CDDP with pBR322 plasmid DNA (Herman
et al., 1988). There are some data available that show that
CDDP resistant cells are not cross resistant with heat (Wall-
ner et al., 1986; Mansouri et al., 1989; GLC4-CDDP unpub-
lished data) therefore the combination of hyperthermia and
CDDP can be of clinical significance. When heat was used as
total body treatment in rats CDDP induced nephrotoxicity
increased, although with optimal heat/drug scheduling an
improved therapeutic index was obtained (Baba et al., 1989).
In mice bearing a murine mammary carcinoma the more
severe side effects of CDDP combined with local hyperther-
mia could be reduced by diethyldithiocarbamate (Murthy et
al., 1987), an agent known to diminish CDDP host toxicity
(Rao et al., 1985). Clinical studies with the combination of
local, intraluminal hyperthermia combined with CDDP (Li &
Hou, 1987) or with CDDP plus radiation (Hou et al., 1989)
for the treatment of oesophageal cancer showed promising
results.
An influence of the polyunsaturated fatty acid docosahexa-
enoic acid (DCHA) on nuclear factors such as DNA confor-
mation was suggested in GLC4-CDDP: after exposure to this
agent increased numbers of interstrand cross-links were pro-
duced by CDDP, in correlation with cytotoxicity in this
resistant line. This effect was not observed in its sensitive
mother line GLC4, although accumulation increased in both
lines (Timmer-Bosscha et al., 1989). For DCHA it was found
that oral administration could bring about changes in human
leukocyte fatty acid composition (Lee et al., 1985), and in
rats changes of tumour cell fatty acid composition were
found (Karmali et al., 1984).
Although DNA conformation can play a role in resistance,
changes in DNA conformation cannot be detected easily,
making them an unlikely parameter, in a search for clinically
feasible detection and modulation of CDDP resistance. How-
ever, modulators affecting for instance topoisomerase II may,
via this enzyme, also indirectly be DNA conformation
modulators.
CDDP analogues
The most widely studied CDDP analogues until now are
carboplatin (CBCDA, cis-diamminecyclobutane-l,1-
dicarboxylatoplatinum(II)) and iproplatin (CHIP, cis-
dichloro-bis-isopropylaminetranshydroxy-platinum(IV)) (for
review: Foster et al., 1990). These compounds showed an
antitumour activity similar to CDDP, but were less potent
than CDDP (Foster et al., 1990). In CDDP resistant cells, in
vitro, there was in general partial or complete cross resistance
for both derivatives (for review: De Graeff et al., 1988). The
rationale for the ongoing clinical development of carboplatin
and iproplatin is that both compounds showed less renal and
gastrointestinal toxicity than CDDP. For both drugs bone
marrow toxicity was dose limiting (Foster et al., 1990). In
new series of analogues the identification of agents that show
activity in tumours resistant to CDDP should have priority.
The 1,2-diamminecyclohexaneplatinum (DACH-Pt) deriva-
tives showed little or no cross resistance in a variety of
CDDP resistant cell lines (for review: De Graeff et al., 1988).
Studies with CDDP resistant and sensitive murine leukaemia
(Kraker & Moore, 1988a), human ovarian and human colon
carcinoma cell lines (Schmidt & Chaney, 1991) showed that
cells with decreased CDDP accumulation were not defective
in DACH-Pt accumulation. In the same cell lines it was
demonstrated that DACH-Pt-DNA adducts were less well
tolerated than CDDP (Schmidt & Chaney, 1991) and ethy-
lene diammine-Pt formed DNA adducts (Gibbons et al.,
1991). The latter compound is supposed to behave cellularly
comparable with CDDP (Eastman, 1983). Repair ofDACH-Pt
induced DNA damage was increased in the CDDP resistant
murine cell line (Gibbons et al., 1991), but not in resistant
human lines (Schmidt & Chaney, 1991). In both the CDDP
resistant murine and human lines repair of CDDP induced
DNA lesions was increased (Schmidt & Chaney, 1991; Gib-
bons et al., 1991). This indicates a role for differences in
accumulation, adduct toxicity and repair in the non-cross
resistance of DACH-Pt analogues. As accumulation defects234 H. TIMMER-BOSSCHA et al.
and increased DNA repair are prevalent mechanisms of
CDDP resistance, DACH-Pt derivatives could be a worth-
while alternative in the treatment of CDDP refractory
tumours. Clinical studies on their applicability have recently
been started.
Third generation platinum analogues that might be an
alternative for the treatment of CDDP refractory tumours
are for instance lobaplatin (D19466, 1,2-bisamminomethyl-
cyclobutaneplatinum(II)-lactate) and enloplatin (CL 287,110;
(SP-4-2)-[1,1-cyclobutanedicarboxylato (2)-O,O'] (tetrahydro-
4H-pyran-4,4-dimethanamine-N,N') platinum). For lobap-
latin only partial cross resistance was found in a CDDP
resistant murine leukaemia cell line (Voegeli et al., 1990). In
our laboratory we observed cross resistance for lobaplatin in
GLC4-CDDP, but none in a CDDP resistant teratocarcinoma
cell line (Meijer et al., 1991). This drug showed activity in
CDDP resistant ovarian cancer in a recent phase I study
(Gietema et al., 1991). Enloplatin was active against CDDP
resistant xenografts of murine leukaemia, and more active
than CDDP against a colon adenocarcinoma in mice (Durr
et al., 1991). Only partial cross resistance was observed in
GLC4-CDDP and in a CDDP resistant teratocarcinoma cell
line (Meijer et al., 1991). In the clinic for lobaplatin no
nephrotoxicity was observed (Gietema et al., 1991).
Conclusions
CDDP resistance as found in the clinic will be multifactorial.
Interactions between several mechanisms identified in vitro
such as signal transduction alterations, oncogenic expression
and activities of DNA repair enzymes have been suggested
(Andrews & Howell, 1990; Scanlon et al., 1989a). Further
research to establish the identity of such resistance cascades
in vitro should be an objective for future research. Finding
the interconnection between resistance mechanisms might
facilitate cancer treatment in more than one way. A cascade
will indicate a starting point in the development of resistance,
an early event that might serve as a focus for the detection of
tumour unresponsiveness. In contrast patient material will
probably show all stages of resistance development in one
tumour.
Analysis in vitro will also indicate the most relevant
modulator(s) that can circumvent tumour resistance, as
interference will be most adequate if it attacks the rate
limiting step in a chain. According to Scanlon (Scanlon et al.,
1989a) the inhibition of the TTP synthesis cycle, the rate
limiting step in the generation of deoxynucleotides for DNA
synthesis, might substantially affect the increased DNA
repair in various CDDP resistant cells. On the other hand
combination of modulators, required for multifactorial
CDDP resistance, can be carried out more efficiently once
knowledge of the relevant interactions is gained. Apart from
this, it should be considered for all combined therapies,
whether in vitro or in vivo that potentiation needs thorough
statistical analysis to distinguish between additivity and
supra-additivity or synergism (Steel & Peckham, 1979). For
VP16 for instance statistical analysis revealed no biochemical
synergism with CDDP (Tsai et al., 1990). In a lot of other
studies due to the limited number of concentrations of the
modulator used, these extensive calculations could not be
made. Based on the article of Steel and Peckham (1979),
conclusions in these studies should be restricted to increased
or not increased, without further specification.
For clinical use optimal doses of these modulators will
have to be established. For the CDDP cytotoxicity increasing
anticancer drugs described in this review, Ara-C, 5-FU, and
VP16 the maximal tolerable doses in combination with
CDDP are well defined. For most of the other drugs required
doses still need to be established and until now published
trials with CDDP modulators are equivocal as far as thera-
peutic results are concerned.
However unexpected mechanisms may play a role in vivo:
Teicher et al. developed CDDP resistance in vivo in mice with
EMT6 murine mammary tumours. Although in vivo a highly
resistant tumour was obtained, no in vitro CDDP resistance
of the cell lines derived from this tumour was observed. The
elimination of CDDP in the resistant EMT6 bearing mice
differed from that in the mice bearing the sensitive cells. As a
consequence the area under the curve of CDDP serum con-
centration vs time of mice bearing EMT6/CDDP was
dramatically decreased, indicating the production of cofac-
tors that enhance clearance of the drug by the resistant cells
(Teicher et al., 1990). Such factors could complicate attempts
of modulation of resistance in the clinic. The mechanisms
underlying this type of resistance and its significance remain
however to be established. Especially in this type of resist-
ance the use of CDDP analogues, that are not only non-cross
resistant in vitro, but in addition have a different mode of
clearance could be worthwhile.
In summary, for modulation of CDDP resistance in the
clinic a growing number of potentially useful agents emerges
from the laboratory bench. It will be important to elucidate
not only resistance mechanisms, but also the possible interac-
tion between these mechanisms. This will facilitate the detec-
tion and modulation of resistance of tumours, as the number
of parameters, that need to be studied, will be reduced and
the effects of (combinations ofmodulators) will become more
predictable.
The impact of the known, potentially useful modulators on
response and survival is eagerly awaited, as is the effect of
third generation Platinum analogues.
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